FGF21, fibroblast growth factor 21, 26291

N. diseases: 236; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental
0.500 Therapeutic disease CTD_human Protective effect of FGF21 on type 1 diabetes-induced testicular apoptotic cell death probably via both mitochondrial- and endoplasmic reticulum stress-dependent pathways in the mouse model. 23499715 2013
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental
0.500 Biomarker disease RGD Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? 23262585 2013
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE This study assessed pegbelfermin (BMS-986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM predisposed to fatty liver. 30520566 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. 30848827 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE GDM and T2DM are proposed to have similar underlying pathophysiologies, raising the question of whether a similar relationship exists between FGF21 and GDM as it does with T2DM. 30346647 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Taken together, our results demonstrate a protective role of pancreatic FGF21 in T2DM mice through inducing PI3K/Akt signaling-dependent insulin expression and secretion. 30461198 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE Higher plasma fibroblast growth factor 21 (FGF21) levels predict incident cardiovascular events in type 2 diabetes patients. 30452928 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE In preclinical models of obesity and type 2 diabetes, treatment with FGF21 improves glucose homeostasis and promotes weight loss, and, as a result, FGF21 has attracted considerable attention as a therapeutic agent for the treatment of metabolic syndrome in humans. 31248786 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE Taken together, this study demonstrates that the intervention to maintain the reduced levels in FGF21 is beneficial for BW reduction in type 2 diabetes patients treated with SGLT2i. 31130574 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE Aerobic and resistance exercise training significantly decreased serum fetuin-A, and fetuin-B, and increased FGF-21 levels in males with type 2 diabetes mellitus. 30888221 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE In this review we focus on circulating FGF21 levels in humans and their associations with disease and clinical parameters, focusing primarily on obesity and obesity-associated diseases such as type-2 diabetes. 31108554 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Pegbelfermin (BMS-986036), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previously been shown to improve markers of metabolism and liver fibrosis in obese patients with type 2 diabetes. 30554783 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE Furthermore, TNF-α, fetuin A, FGF-21 were altered in obese children with T2DM suggesting a direct involvement in β-cell failure. 31276632 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Overall, the findings of this study demonstrate that p.o. administration of HRI activators, by increasing FGF21, is a promising strategy for the treatment of type 2 diabetes mellitus and non-alcoholic fatty liver disease. 30927369 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE Meta-analysis revealed that, compared with the control group, the T2DM group had a significantly higher plasma/serum FGF-21 level (p < 0.001), with the SMD of 1.34% and 95% CI (0.70 to 1.98). 30918117 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE FGF21-based drugs induce weight loss and improve dyslipidemia in patients with obesity and T2D, and reduce steatosis in patients with NASH. 30893110 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Our study describes a structure-based chimerisation approach that effectively mitigates both the intrinsically weak receptor binding affinities and short half-lives of endocrine FGFs, and advance the development of the FGF21 hormone into a potentially useful drug for Type 2 diabetes. 31631034 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE The aims of our study were to test whether dietary MR in the context of a high-fat regimen protects against type 2 diabetes in mice and to investigate whether vegan and vegetarian diets, which have naturally low methionine levels, modulate circulating FGF21 in humans. 30841758 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE FGF21 receptor expression and postreceptor signaling in different fat deposits of both control and T2DM subjects were analyzed. 31798902 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Fibroblast growth factor-21 (FGF-21) is a potential cytokine for type II diabetes mellitus. 30415427 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE Univariate linear analysis revealed that hypertension, BMI, WC, body fat mass, SBP, DBP, logarithmically transformed TG (log-TG), low-density lipoprotein cholesterol (LDL-C) level, log-glucose, log-creatinine, log-UACR, log-insulin, and log-HOMA-IR positively correlated, whereas HDL-C and eGFR negatively correlated with serum FGF21 levels in T2DM patients. 31582974 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE In recent clinical trials, an FGF21 analogue reduced insulin levels and body weight, and ameliorated dyslipidemia in patients with type 2 diabetes mellitus and obesity, all of which are well-known risk factors for kidney disease. 29108880 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Recombinant FGF21 Protects Against Blood-Brain Barrier Leakage Through Nrf2 Upregulation in Type 2 Diabetes Mice. 30022432 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE Serum FGF21 level was evaluated in patients with type 2 diabetes (T2D) receiving exenatide treatment. 30827929 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Therefore, we investigated the effect of FGF21 on endothelial function in both type 1 and type 2 diabetes. 31511499 2019